A Phase 3, Multi-Center, Randomized, Open-Label Study of Carbavance (Meropenem/Vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae

Trial Profile

A Phase 3, Multi-Center, Randomized, Open-Label Study of Carbavance (Meropenem/Vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Oct 2017

At a glance

  • Drugs Meropenem/vaborbactam (Primary)
  • Indications Enterobacteriaceae infections
  • Focus Registrational; Therapeutic Use
  • Acronyms TANGO 2
  • Sponsors Rempex Pharmaceuticals; The Medicines Company
  • Most Recent Events

    • 08 Oct 2017 Results presented at the IDWeek 2017.
    • 08 Oct 2017 Results comparing clinical responses in patients with renal impairment enrolled in TANGO I and II studies, presented at the IDWeek 2017.
    • 08 Oct 2017 Results (n=72) assessing clinical outcomes of serious infections presented at the IDWeek 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top